Milestone Pharmaceuticals' CARDAMYST Nasal Spray Added to Express Scripts National Formularies
β’ Express Scripts added CARDAMYST (etripamil) nasal spray to its commercial national formularies effective March 27, 2026, expanding access for commercially insured patients. β’ The FDA-approved self-administered spray converts acute paroxysmal supraventricular tachycardia (PSVT) episodes to sinus rhythm in adults. β’ This coverage decision makes the first-in-class treatment broadly affordable across the U.S., improving cardiovascular care options.
Read original Β· investors.milestonepharma.com
